Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA collaborates with THD to provide critical aid to hematologists

The Hague (Netherlands), June 23, 2023. The European Hematology Association (EHA) is proud to announce its partnership with the Türk Hematoloji Derneği (THD) in a joint effort to support hematologists working in earthquake-affected areas in Türkiye and Syria.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more